Jump to accessibility statement Skip to content

Senior Lecturer in Biochemistry

I joined the School of Pharmacy, Pharmaceutical and Cosmetic Sciences as a Senior Lecturer in Biochemistry in 2016. I graduated from Queen Mary (University of London) in 2001 with a BSc (Hons) in Biochemistry and completed my PhD in 2005 from the Northern Institute for Cancer Research, University of Newcastle where I developed small molecule inhibitors targeting protein-protein interaction for the treatment of cancers.

I then undertook postdoctoral research at the University of York investigating basal signalling pathways to identify drug development targets in cancers and contributed to the undergraduate teaching programme. I then moved to CRUK Beaton Institute, Glasgow in 2011 as a postdoctoral researcher and then relocated to the Institute of Cancer Sciences, University of Glasgow.

My primary research interest is on Glioblastomas; an incurable brain tumour. My laboratory use treatment resistant cells to identify novel pathways that can be targeted for the development of new therapeutics for the treatment of cancers.


Teaching and supervision

Undergraduate programmes

MPharm Pharmacy
BSc Biopharmaceutical Science
BSc Cosmetic Science

Postgraduate programmes

MSc Drug Discovery and Development 
MSc Pharmaceutical and Biopharmaceutical Formulation


Current PhD students

Najla Yussuf Moosa

Identification of metabolic pathways in glioblastoma stem-like cells during the process of tumour growth.

Sara Azeem

Identification of metabolic signatures in high grade gliomas for therapeutic exploitation.

Research interests for potential research students

Metabolomics studies in Glioblastoma stem cells (GSCs)
DNA damage response in GSCs
Repurposing existing drugs to target Glioblastoma

Research

My main research focus is in the development and identification of novel therapeutics for the treatment of Glioblastomas (GBMs). GBMs are the most common form of primary brain tumour in adults. Despite optimal treatment consisting of surgery, chemotherapy and radiotherapy tumour recurrence is inevitable. This is thought to be driven by a population of GBM stem-like cells (GSCs) which are resistant to the therapies and can give rise to new tumours.

My research has identified optimal strategies to target GSC population and revealed distinct metabolic alterations in GSCs circuitry. My current research focuses on metabolomics, DNA damage signalling, high throughput siRNA and drug library screening in GSCs with the aim to identify and develop novel therapeutics to improve the outcomes for patients with glioblastoma.

Publications

Number of items: 17.

Article

Carruthers, Ross D., Ahmed, Shafiq, Ramachandran, Shaliny, Strathdee, Karen, Kurian, Kathreena M., Hedley, Ann, Gomez-Roman, Natividad, Kalna, Gabriela, Neilson, Mathew, Gilmour, Lesley, Stevenson, Katrina H., Hammond, Ester M. and Chalmers, Anthony J. (2018) Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells. Cancer Research, 78 (17). pp. 5060-5071. ISSN 0008-5472

Ahmed, Shafiq, Carruthers, R., Biasoli, D., Gomez-Roman, N., Gilmour, L., Strathdee, K., Hedley, A., Kalna, G., Hammond, E. and Chalmers, A. J. (2016) P08.36 Radioresistance of glioblastoma stem-like cells is associated with DNA replication stress, which is a promising therapeutic target. Neuro-Oncology, 18 (s4). iv49. ISSN 1522-8517

Kaur, A., Denisova, O., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, Shafiq, Raheem, O., Haapasalo, H. K., Eriksson, J., Chalmers, A. J., Laakkonen, P. M. and Westermarck, J. (2016) PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Research, 76 (23). pp. 7001-7011. ISSN 0008-5472

Tardito, S, Oudin, A, Ahmed, Shafiq, Fack, F, Keunen, O, Zheng, L, Miletic, H, Sakariassen, P, Weinstock, A, Wagner, A, Lindsay, S, Hock, A, Barnett, S, Ruppin, E, Morkve, S, Lund-Johansen, M, Chalmers, A, Bjerkvig, R, Niclou, S and Gottlieb, E (2015) Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restriced glioblastoma. Nature Cell Biology, 17 (12). pp. 1556-1568. ISSN 1556-1568

Carruthers, R, Ahmed, Shafiq, Strathdee, Karen, Gomez-Roman, N, Amoah-Buahin, E, Watts, C and Chalmers, A (2015) Abrogation of radioresistance in in glioblastoma stem-like cells by inhibition of ATM kinase. Molecular Oncology, 9 (1). pp. 192-203. ISSN 1878-0261

Ahmed, Shafiq, Carruthers, R, Gilmour, L, Yildirim, S, Watts, C and Chalmers, A (2015) Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells. Cancer Research, 75 (20). pp. 4416-4428. ISSN 0008-5472

Ichim, G, Lopez, J, Ahmed, Shafiq, Muthalagu, N, Giampazolias, E, Delgado, E, Haller, Martina, Riley, Joel S, Mason, Susan, Athineos, Dimitris, Parsons, MJ, Kooij, BVD, Bouchier-Hayes, L, Chalmers, A, Rooswinkel, R, Oberst, A, Blyth, K, Rehm, M, Murphy, D and Tait, S (2015) Limited mitochondrial permeabilisation causes DNA-damage and genomic instability in the absence of cell death. Molecular Cell, 57 (5). pp. 860-872. ISSN 1097-2765

Blackburn, TJ, Ahmed, Shafiq, Coxon, CR, Liu, J, Lu, X, Golding, BT, Griffin, RJ, Hutton, C, Newell, DR, Ojo, S, Watson, AF, Zaytzev, A, Zhao, Y, Lunec, J and Hardcastle, IR (2013) Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions. Med. Chem. Commun., 4 (9). pp. 1297-1304.

Shah, Z, Ahmed, Shafiq, Ford, J, Allison, S, Knight, J and Milner, J (2012) A Deacetylase-Deficient SIRT1 Variant Opposes Full-Length SIRT1 in Regulating Tumor Suppressor p53 and Governs Expression of Cancer-Related Genes. Mol Cell Biol., 32 (3). pp. 704-716.

Hardcastle, IR, Liu, J, Valeur, E, Watson, A, Ahmed, Shafiq, Blackburn, TJ, Bennaceur, K, Clegg, W, Drummond, C, Endicott, JA, Golding, BT, Griffin, RJ, Gruber, J, Haggerty, K, Harrington, RW, Hutton, C, Kemp, S, Lu, X, McDonnell, JM, Newell, DR, Noble, ME, Payne, SL, Revill, CH, Riedinger, C, Xu, Q and Lunec, J (2011) Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency. J Med Chem, 54 (5). pp. 1233-43.

Lynch, CJ, Shah, ZH, Allison, SJ, Ahmed, Shafiq, Ford, J, Warnock, LJ, Li, H, Serrano, M and Milner, J (2010) SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS ONE, 4 (10).

Ahmed, Shafiq and Milner, J (2009) Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS ONE, 4 (10).

Ford, J, Ahmed, Shafiq, Allison, S, Jiang, M and Milner, J (2008) JNK2 dependent regulation of SIRT1 protein stability. Cell Cycle, 7 (19). pp. 3091-3097.

Hardcastle, IR, Ahmed, Shafiq, Atkins, H, Farnie, G, Golding, BT, Griffin, RJ, Guyenne, S, Hutton, C, Kallblad, P, Kemp, SJ, Kitching, MS, Newell, DR, Norbedo, S, Northen, JS, Reid, RJ, Saravanan, K, Willems, HM and Lunec, J (2006) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem, 49 (21). pp. 6209-6221.

Hardcastle, IR, Ahmed, Shafiq, Atkins, H, Calvert, AH, Curtin, NJ, Farnie, G, Golding, BT, Griffin, RJ, Guyenne, S, Hutton, C, Kallblad, P, Kemp, SJ, Kitching, MS, Newell, DR, Norbedo, S, Northen, JS, Reid, RJ, Saravanan, K, Willems, H and Lunec, J (2005) Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. Bioorganic & Medicinal Chemistry Letters, 15 (5). pp. 1515-1520.

Conference or Workshop Item

Mysina, Svetlana, Ahmed, Shafiq, Michaelis, Martin, Cinatl Jr, Jindrich, Adejuwon, Damilola, Zaka, Masood and Carr-Wilkinson, Jane (2018) Investigating the role of cancer stem cell related genes in acquired drug resistance in neuroblastoma. In: Advances in Neuroblastoma Research 2018, May 9th -12th 2018, San Francisco.

Ahmed, Shafiq (2016) High throughput screening campaigns for the development of novel therapeutics in Glioblastomas. In: Academic Screening Group Meeting, 6 May 2016, CRUK Manchester. (Unpublished)

This list was generated on Sat Jun 6 14:17:53 2020 BST.
DNA damage signalling in cancers
Cancer metabolism
3D tumour models
High throughput siRNA and drug screening

Editorial and Review board
Journal of Cellular & Molecular Oncology
OncoTargets and Therapy

Memberships
American Association for Cancer Research (AACR)
European Association for Cancer Research (EACR)
British Association for Cancer Research (BACR)

Last updated 11 June 2019

ReciteMe accessibility toolbar button